When was aTyr Pharma founded?

aTyr Pharma was founded in 2005 and raised its 1st funding round within a year of its incorporation.

Where is aTyr Pharma located?

aTyr Pharma is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does aTyr Pharma have?

As of Sep 30, 2026, the latest employee count at aTyr Pharma is 66.

Is aTyr Pharma a funded company?

aTyr Pharma is a funded company, having raised a total of $172M across 9 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 2005.

When was the latest funding round of aTyr Pharma?

aTyr Pharma's latest funding was a $***** Post IPO round on Aug 28, 2017, with participation from 3 investors. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $1.24B in funding in 2026 to date.

What is the annual revenue of aTyr Pharma?

Annual revenue of aTyr Pharma is less than $1M as on Dec 31, 2025

Where does aTyr Pharma rank among its competitors?

aTyr Pharma ranks 521st amongst 3785 active competitors, of which 1225 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Tango Therapeutics, which secured $15M in Oct, 2025.

Who are the top competitors of aTyr Pharma?

aTyr Pharma's top competitors include BridgeBio, Jazz Pharmaceuticals and Alnylam. Among them, Tango Therapeutics secured the most recent funding round in October, 2025.

aTyr Pharma - 2026 Company Profile, Team, Funding, Competitors & Financials

aTyr Pharma is a public company based in San Diego (United States), founded in 2005 by Paul Schimmel and Xiang Lei Yang. It operates as a Developer of protein biologics for treating multiple rare diseases. aTyr Pharma has raised $172M in funding from investors like Polaris Partners, Sofinnova Investments and Alta Partners. The company has 3785 active competitors, including 1225 funded and 894 that have exited. Its top competitors include companies like BridgeBio, Jazz Pharmaceuticals and Alnylam.

Company Details

Developer of protein biologics for treating multiple rare diseases. The drug candidates include ATYR2810 for solid tumors, ATYR1923 for Pulmonary Sarcoidosis, COVID-19 related severe respiratory complications, and others.

Website: atyrpharma.com
Social
Registered Address: San Diego, California

Key Metrics

Founded Year

2005

Location

San Diego, United States

Stage

Public

Total Funding

$172M in 9 rounds

Latest Funding Round

Post IPO, Aug 28, 2017, $*****

Investors

Polaris Partners & 15 more

Ranked

521^st among 3785 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2025

Employee Count

66 as on Sep 30, 2026

Similar Companies

BridgeBio & 3461 more

Exit Details

Public

View aTyr Pharma's full profile

aTyr Pharma is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Atyr Pharma Inc CIN: 1339970 , United States, Active	Sep 07, 2005	$0 - $1M (As on Dec 31, 2025)	-	-
Atyr Pharma, Inc. CIN: 203435077 , United States, Active	Dec 26, 999	-	56 (As on Dec 31, 2024)	-

aTyr Pharma got listed on May 07, 2015.

Click here to take a look at aTyr Pharma's IPO in detail

aTyr Pharma has raised a total funding of $172M over 9 rounds. Its first funding round was on Sep 2005. Its latest funding round was a Post IPO round on Aug 28, 2017 for $*****. 3 investors participated in its latest round. aTyr Pharma has 16 institutional investors.

Here is the list of recent funding rounds of aTyr Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 28, 2017	4183789	Post IPO	7495832	7362374	5399340	9808474
Nov 21, 2016	9638224	Post IPO	4687409	8101401	3122291	SLR Investment Corp
Mar 31, 2015	8731181	Series E	6967297	6709013	Sofinnova Investments	T. Rowe Price & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of aTyr Pharma's funding rounds and investors

The founders of aTyr Pharma are Paul Schimmel and Xiang Lei Yang.

Here are the details of aTyr Pharma's key team members:

Paul Schimmel: Co-Founder of aTyr Pharma and founder of 1 other company.
Xiang Lei Yang: Co-Founder of aTyr Pharma.

View details of aTyr Pharma's Founder profiles and Board Members

aTyr Pharma's employee count trend

aTyr Pharma has 66 employees as of Sep 26. Here is aTyr Pharma's employee count trend over the years:

Uncover aTyr Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of aTyr Pharma include BridgeBio, Jazz Pharmaceuticals and Alnylam. Here is the list of Top 10 competitors of aTyr Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 22 others	82/100
2nd	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
3rd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 14 others	81/100
4th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
5th	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
6th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 29 others	73/100
7th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
8th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	72/100
9th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
10th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	72/100
521st	aTyr Pharma 2005, San Diego (United States), Public	Developer of protein biologics for treating multiple rare diseases	$172M	T. Rowe Price, Redmile Group & 14 others	53/100